Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GTP Regimen in Refractory/Recurrent HLH
NCT06038422Phase 3Unknown
- Sponsor
- Beijing Friendship Hospital
- Start
- Sep 2023
- Primary completion
- Sep 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
A Phase 3 trial of emapalumab in hemophagocytic lymphohistiocytosis (HLH), sponsored by Beijing Friendship Hospital. Status: unknown.
02
Drugs
emapalumab
03
Conditions
hemophagocytic lymphohistiocytosis (HLH)
Beyond the preview
Go deeper on NCT06038422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06038422.